Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Yusuke Mizuuchi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1460-7404; OpenAlex author ID A5077236645. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 3 papers · 2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 10

  1. uPAR expression in M-MDSCs under high LDHA activity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-025-29823-4↗
  2. Minimally invasive distal pancreatectomy for pancreatic cancer: cranial-to-caudal approach with identification of Gerota's fascia (with video). Co-author DOI 10.1007/s00464-023-10438-7↗
  3. Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses. Co-author DOI 10.1186/s13046-022-02301-9↗
  4. Autophagy Is Required for Activation of Pancreatic Stellate Cells, Associated With Pancreatic Cancer Progression and Promotes Growth of Pancreatic Tumors in Mi… Co-author DOI 10.1053/j.gastro.2017.01.010↗
  5. Extra-pancreatic invasion induces lipolytic and fibrotic changes in the adipose microenvironment, with released fatty acids enhancing the invasiveness of pancr… Co-author DOI 10.18632/oncotarget.15430↗
  6. Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and … Co-author DOI 10.1002/ijc.30075↗
  7. CD146 attenuation in cancer-associated fibroblasts promotes pancreatic cancer progression. Co-author DOI 10.1002/mc.22409↗
  8. Overexpression of microRNA-5100 decreases the aggressive phenotype of pancreatic cancer cells by targeting PODXL. Co-author DOI 10.3892/ijo.2016.3389↗
  9. Anterior gradient 2 downregulation in a subset of pancreatic ductal adenocarcinoma is a prognostic factor indicative of epithelial-mesenchymal transition. Co-author DOI 10.1038/labinvest.2014.138↗
  10. Follicular pancreatitis, report of a case clinically mimicking pancreatic cancer and literature review. Co-author DOI 10.1016/j.prp.2013.09.005↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenoki Ohuchida · 8 shared papers, 2015–2025 · strength 0.77
  2. Yoshinao Oda · 8 shared papers, 2015–2025 · strength 0.65
  3. Kohei Nakata · 5 shared papers, 2017–2025 · strength 0.62
  4. Naoki Ikenaga · 3 shared papers, 2022–2025 · strength 0.52
  5. Masafumi Nakamura · 5 shared papers, 2016–2023 · strength 0.47
  6. Chika Iwamoto · 4 shared papers, 2017–2025 · strength 0.44
  7. Toshiya Abe · 4 shared papers, 2017–2023 · strength 0.42
  8. Noboru Ideno · 2 shared papers, 2022–2023 · strength 0.31
  9. Hideya Onishi · 2 shared papers, 2016–2025 · strength 0.26
  10. Takao Ohtsuka · 5 shared papers, 2014–2017 · strength 0.25
  11. Bo Zhang · 1 shared paper, 2025 · strength 0.20
  12. Chikanori Tsutsumi · 1 shared paper, 2025 · strength 0.20
  13. Masafumi Nakamura · 1 shared paper, 2025 · strength 0.20
  14. Masao Tanaka · 4 shared papers, 2014–2016 · strength 0.20
  15. Koji Shindo · 2 shared papers, 2015–2022 · strength 0.18
  16. So Nakamura · 1 shared paper, 2023 · strength 0.18
  17. Masafumi Nakamura · 1 shared paper, 2023 · strength 0.18
  18. Makoto Hashizume · 3 shared papers, 2016–2017 · strength 0.16
  19. Yoshihiro Miyasaka · 3 shared papers, 2016–2017 · strength 0.16
  20. Tomohiko Shinkawa · 1 shared paper, 2022 · strength 0.13
  21. Yuki Mochida · 1 shared paper, 2022 · strength 0.13
  22. Lin Cui · 2 shared papers, 2016 · strength 0.11
  23. Sho Endo · 2 shared papers, 2017 · strength 0.11
  24. Takashi Okumura · 2 shared papers, 2017 · strength 0.11
  25. Masafumi Sada · 2 shared papers, 2017 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.